Matthew Trainor, MD
Nephrology · Worcester, MANPI 1013990084
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,925 of the $26,167 with a category attached, or 68.5%. Nxstage Medical, Inc. accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $17,360 and has fallen 82.0% since, to $3,126 in 2024.
Across 26 payments — averaging $1006.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nxstage Medical, Inc.$26K
- AstraZeneca$16
Across 8 payments — averaging $6654.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fresenius USA Marketing, Inc.$41K
- Fresenius Medical Care Renal Therapies Group, LLC.$12K
What the payments were for
- Consulting fees$17,92569%
- Speaking & faculty fees$3,50013%
- Travel & lodging$3,78514%
- Food & beverage$9574%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nxstage Medical, Inc. | 25 | $26,151 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$25,540
- NXSTAGE PUREFLOW SOLUTION$294
- NXSTAGE CARTRIDGE EXPRESS$175
- PUREFLOW SL$111
How this compares
$26,167 in reported general payments places this provider in the 85th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 26 | $90,016 |
| Sevelamer Carbonate | 91 | $21,690 |
| JardianceEmpagliflozin | 17 | $14,801 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,899 |
| Torsemide | 54 | $1,427 |
| Losartan Potassium | 83 | $1,106 |
| Chlorthalidone | 39 | $1,014 |
| Furosemide | 48 | $559 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $445 |
| Amlodipine Besylate | 64 | $434 |
| Lisinopril | 56 | $400 |
| Potassium Chloride | 12 | $343 |
| Spironolactone | 27 | $317 |
| Calcitriol | 27 | $308 |
| Allopurinol | 28 | $157 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Worcester
- Anil ChandrakerWorcester$162K
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.